

₹129.50
Moxifloxacin Hydrochloride (Eq. to Moxifloxacin) 5.0 mg + Dexamethasone sodium phosphate (Eq. to Dexamethasone phosphate)1.0mg +sterile aqueous base q. s.
5 ml with carton
PRAIVA D Eye Drops
Composition:- Moxifloxacin Hydrochloride (Eq. to Moxifloxacin) 5.0 mg + Dexamethasone sodium phosphate (Eq. to Dexamethasone phosphate) 1.0mg + sterile aqueous base q.s.
PRAIVA D Eye Drops – Moxifloxacin Hydrochloride & Dexamethasone Phosphate Eye Drops is a potent ophthalmic combination of a fourth-generation fluoroquinolone antibiotic and a corticosteroid, formulated to effectively treat bacterial eye infections while controlling associated inflammation. This combination supports rapid microbial clearance along with relief from redness, swelling, and irritation.
Key Points of Moxifloxacin Hydrochloride & Dexamethasone Phosphate Eye Drops – PRAIVA D Eye Drop
• Broad-Spectrum Antibacterial Action: Moxifloxacin provides rapid and effective coverage against Gram-positive and Gram-negative ocular pathogens.
• Powerful Anti-Inflammatory Effect: Dexamethasone controls inflammation, reducing redness, edema, and discomfort.
• Rapid Symptom Relief & Healing: Combines infection control with inflammation management for faster recovery.
• Ideal for Post-Operative & Severe Infections: Suitable for managing post-surgical inflammation and infection risk.
Can be Prescribed by:
• Ophthalmologists
• Eye Surgeons
• General Physicians
• Optometrists
• Healthcare practitioner
Disclaimer: To be used strictly under the guidance of a qualified healthcare professional. For prescription use only. Not intended for public marketing or promotion.
Chlorpheniramine Maleate0.01%w/v+Naphazoline Hydrochloride0.05%w/v+Camphor 0.01%w/v+Carboxymethyl cellulose 0.02%w/v
5 ml with carton
Moxifloxacin Hydrochloride (Eq. to Moxifloxacin) 0.5% w/v+Ketorolac Tromethamine 0.4% w/v+Stabilized Oxychloro Complex 0.005% w/v (As Preservative)Sterile aqueous base q. s.
Moxifloxacin 0.5% +Loteprednol Etabonate 0.5% +Benzalkonium chloride 0.2%
Reviews
There are no reviews yet.